The FDA cleared Access MeMed BV, a host-response blood test that helps distinguish bacterial from viral infections in adults and children in as little as 15 minutes.
News|Slideshows|August 19, 2020
Adult Pneumococcal Vaccine 2020: 5 Questions on ACIP Update
Author(s)Terry Brenneman, MD
Pneumococcal vaccine should still be given to adults aged ≥65 years, but no longer to all adults in that population. Find out what you know - and what you may need to know.
Advertisement
The Advisory Committee on Immunization Practices (ACIP) in November 2019 again updated its recommendations for pneumococcal vaccination among adults aged ≥65 years.
The update amends the ACIP’s 2014 statement that recommended routine use of the pneumococcal conjugate vaccine (PCV13) in series with pneumococcal polysaccharide vaccine (PPSV23) for all adults in this age range. For a brief review of the full history,
To find out what you know-and might need to know-about administration this year, try the 5 questions that follow.
Advertisement
Related to this article
Catch up on the 9 FDA drug approvals most relevant to primary care, including new options for HIV-1 infection, narcolepsy, diabetes, pain management, and more.
AHA 2026: Yoga-based cardiac rehabilitation improved quality of life and walking distance in patients with HFrEF but did not significantly reduce death, hospitalization, or stroke.
The ACS 2026 prostate cancer screening guidelines recommend risk-based PSA testing beginning at age 45 or 50, with updated follow-up thresholds.
Retatrutide trials report less knee osteoarthritis pain; ixekizumab plus tirzepatide shows exploratory ACR50 benefits in psoriatic arthritis.
Asundexian reduced relative ischemic stroke risk by 26% alongside antiplatelet therapy, with bleeding concerns in older adults.
Survodutide demonstrated cardiovascular safety vs placebo in the phase 3 SYNCHRONIZE-CVOT trial, with improvements in weight and cardiometabolic risk factors.
Evolocumab was associated with a 20% lower risk of fatal or nonfatal myocardial infarction than ezetimibe among more than 544 000 adults with ASCVD.
Advertisement
Advertisement
Trending on Patient Care Online
1
American Cancer Society Updates Prostate Cancer Screening Guidelines
2
FDA Approves Asundexian for Stroke Prevention After Ischemic Stroke or TIA
3
Yoga-Based Cardiac Rehab Improves Quality of Life in Heart Failure Trial
4
Retatrutide Phase 3 Trials Report Reduced Knee Osteoarthritis Pain
5